MS
Sanofi moves teriflunomide into phase III MS trials
October 26, 2010Research and Development MS, Sanofi, Sanofi-Aventis, TERACLES, multiple sclerosis, relapsing multiple sclerosis, teriflunomide
Sanofi-Aventis is to begin the first phase III study of an oral drug as an add-on to standard therapy in …
Gilenya approved in Russia, awaits FDA decision
September 16, 2010Sales and Marketing Cladribine, Gilena, MS
Novartis has won approval for its MS drug Gilenya in Russia but still awaits the FDA’s decision on its fate …
Cohn & Wolfe wins MS account
August 20, 2010Medical Communications Cohn & Wolfe, Genzyme, MS
Cohn & Wolfe has won a global account with Genzyme to handle communications for its work with alemtuzumab in multiple …
Merck KGaA’s oral MS therapy gains US priority review
July 29, 2010Sales and Marketing Cladribine, MS, Merck KGaA
Merck’s cladribine has been granted a priority review status by the FDA in a move that could see it come …
First oral MS treatment approved in Russia
July 12, 2010Sales and Marketing Cladribine, MS, Merck Serono, Movectro
Regulators in Russia have approved Merck Serono’s cladribine, lining up the drug to be the first oral treatment for multiple …
Gilenia on track to become first oral MS drug
June 11, 2010Sales and Marketing Gilenia, MS
Novartis’ oral MS therapy Gilenia has been boosted by an FDA committee’s unanimous recommendation for its approval. The drug is …
Merck Serono resubmits oral MS therapy to FDA
June 8, 2010Research and Development Cladribine, MS, Merck KGaA
Merck Serono has re-submitted its oral multiple sclerosis therapy cladribine to US regulators. Merck Serono, a Swiss division of Merck …
Global MS awareness campaign launched
June 1, 2010Medical Communications MS, Merck Serono
Merck Serono has launched a short film competition as part of a global campaign, Real MS, to raise awareness of …
Evotec wins grant to advance H3 receptor antagonist
May 4, 2010Research and Development CNS, Evotec, MS
Evotec is to receive funding of up to 1.5 million euros from a German government fund to advance its H3 …
Trial boost for Merck KGaA’s cladribine
April 19, 2010Research and Development Cladribine, MS, Merck KGaA, Merck Serono
New data from German pharma company Merck suggests its oral multiple sclerosis treatment cladribine has been successful in treating relapsing …
Gilenia cuts relapse rates in MS patients
April 14, 2010Sales and Marketing Gilena, MS, Novartis
Novartis’ new oral multiple sclerosis treatment Gilenia has been shown to reduce relapse rates significantly in new trial data.Data presented …
Novartis gains edge in MS treatment race
February 22, 2010Research and Development, Sales and Marketing Cladribine, Gilenia, MS, Novartis
Novartis’ new oral multiple sclerosis treatment Gilenia will be given a priority review by the FDA.This could lead to a …
Cladribine still set to be first oral MS treatment
January 18, 2010Sales and Marketing Cladribine, FTY-720, MS, Merck Serono
Merck Serono’s new oral treatment for multiple sclerosis cladribine is still tipped to reach the market ahead of its rival, …
Biogen submits Fampridine PR to European regulators
January 14, 2010Sales and Marketing Biogen, Fampridine, MS
Biogen Idec is seeking European approval for a drug which helps multiple sclerosis sufferers to walk better. A marketing authorisation …
Novartis’ Extavia approved in US
August 19, 2009Research and Development, Sales and Marketing Extavia, MS, Novartis
Novartis has received US approval for its betaferon product for multiple sclerosis.Extavia’s active ingredient is interferon beta-1b, putting it into …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
